DIABETES PIPELINE ANALYSIS – MERCK
ozmosi_admin2017-08-28T20:39:22+00:00Merck’s two blockbuster diabetes products, Janumet® and Januvia®, are DPP-4 inhibitors that generated nearly $3.3 billion in Sales in 2016.3 Januvia® is especially known for its great cardiovascular safety profile, which has helped differentiate itself in its class. But Merck has no plans of stopping there with four different products in late stage development that appear to be promising. In conjunction with Pfizer, the company recently filed NDAs for three SGLT-2 inhibitors based on their ertugliflozin molecule – one as a monotherapy, another in combination with Januvia® (sitagliptin) and the third a combination with metformin. Despite expectations to launch with three [...]